4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.
4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.
For more information, please visit www.4biocapital.com
Company Details
- Employees
- 19
- Founded
- 2014
- Address
- 78 Pall Mall, London,england,united Kingdom
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- 4biocapital.com
- HQ
- London, England
4bio Capital Questions
4Bio Capital's website is 4biocapital.com
4Bio Capital's LinkedIn profile is https://uk.linkedin.com/company/4bio-capital
4Bio Capital has
19 employees.
View email and phone details for 19
employees at 4Bio Capital.
4Bio Capital's industry is
Venture Capital and Private Equity Principals
4Bio Capital's top competitors are
Mission Biocapital,
Syncona Limited,
Hadean Ventures,
Bioqube Ventures,
Sofinnova Partners,
Abingworth,
Kerna Ventures,
Advent Life Sciences,
M Ventures,
Granite Asia.
4Bio Capital's categories are Venture Capital and Private Equity Principals
4Bio Capital's founding year is 2014
